COMPUGEN Return on Average Equity Trend from 2010 to 2020

<div class='circular--portrait' style='background:#82ADFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>CO</div>
CGEN -- Israel Stock  

ILA 4,802  273.00  5.38%

COMPUGEN Return on Average Equity is decreasing over the years with very volatile fluctuation. Ongoing Return on Average Equity is expected to grow to -0.78 this year. From 2010 to 2020 COMPUGEN Return on Average Equity quarterly data regression line had arithmetic mean of(45.88) and significance of  0.95. The current year Direct Expenses is expected to grow to about 1 M, whereas Net Income is expected to decline to (30.3 M).

Search Historical Trends

 
Refresh
Check COMPUGEN financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Direct Expenses of 1 M, Revenues of 657.7 K or Weighted Average Shares of 62.4 M, as well as many exotic indicators such as PPandE Turnover of 3.18, Receivables Turnover of 172 or Accounts Payable Turnover of 5.41. This can be a perfect complement to check COMPUGEN Valuation or Volatility. It can also complement various COMPUGEN Technical models. Continue to Trending Equities.

COMPUGEN Return on Average Equity Marginal Breakdown

Showing smoothed Return on Average Equity of COMPUGEN with missing and latest data points interpolated. Return on equity measures a corporation's profitability by calculating the amount of net income available to common stockholders returned as a percentage of [EquityAvg].
View

(78.07) 

          10 Years Trend
Decreasing
Very volatile
 Return on Average Equity 
      Timeline 

COMPUGEN Return on Average Equity Regression Statistics

Arithmetic Mean(45.88)
Coefficient Of Variation(58.53)
Mean Deviation 22.73
Median(50.16)
Standard Deviation 26.85
Sample Variance 721.09
Range 79.09
R-Value(0.020988)
Mean Square Error 800.86
R-Squared 0.0004405
Significance 0.95
Slope(0.17)
Total Sum of Squares 7,211

COMPUGEN Return on Average Equity Over Time

2010 (25.87) 
2011 (50.16) 
2012 (73.16) 
2013 (56.83) 
2014 (16.08) 
2015 (20.57) 
2016 (41.07) 
2017 (79.87) 
2018 (67.93) 
2019 (72.35) 
2020 (0.78) 

About COMPUGEN Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include COMPUGEN income statement, its balance sheet, and the statement of cash flows. COMPUGEN investors use historical funamental indicators, such as COMPUGEN's Return on Average Equity, to determine how well the company is positioned to perform in the future. Although COMPUGEN investors may use each financial statement separately, they are all related. The changes in COMPUGEN's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on COMPUGEN's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on COMPUGEN Financial Statements. Understanding these patterns can help to make the right decision on long term investment in COMPUGEN. Please read more on our technical analysis and fundamental analysis pages.

Current Sentiment - CGEN

COMPUGEN Investor Sentiment

Macroaxis portfolio users are unresponsive in their opinion about investing in COMPUGEN. What is your opinion about investing in COMPUGEN? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

COMPUGEN Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for COMPUGEN and EVOGENE LTD. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
 2017 2018 2019 2020 (projected)
Accounts Payable3.44 M2.95 M1.09 M1.12 M
Receivables34 K167 K341 K349.97 K
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 61 people.
Continue to Trending Equities. Please also try Theme Ratings module to determine theme ratings based on digital equity recommendations. macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page